Etoposide in recurrent childhood Langerhans' cell histiocytosis: An Italian cooperative study
Authors:
- 15 December 1988
- Vol. 62 (12) , 2528-2531
Abstract
Eighteen evaluable children with recurrent Langerhans'' cell histiocytosis (LCH) which was resistant to standard therapy, were treated with etoposide (VP 16-213), 200/mg/m2/day for 3 days every 3 weeks, to study the efficacy and toxicity of this drug. Complete and partial responses were demonstrated in 15 patients (83.3%). Only one of the 12 children achieving a complete remission has relapsed. No dose-limiting major toxicities were registered. Although etoposide might be an effective treatment in recurrent LCH which needs a chemotherapeutic approach, it is emphasized that this drug must be used carefully.Keywords
This publication has 35 references indexed in Scilit:
- Treatment of lymphohistiocytic erythrophagocytosis with VP-16 and aziridinylbenzoquinoneMedical and Pediatric Oncology, 1987
- Monocytic leukemia in infancy. A review of eight childrenCancer, 1985
- Malignant histiocytosis resistant to anthracycline. Response to intensive treatment with etoposide and amsacrineArchives of internal medicine (1960), 1985
- Etoposide (VP-16–213)New England Journal of Medicine, 1985
- Impaired natural killer activity in lymphohistiocytosis syndromeThe Journal of Pediatrics, 1984
- Histiocytosis X in children: Patterns of disease and results of treatmentMedical and Pediatric Oncology, 1983
- Chlorambucil in histiocytosis X: A Southwest Oncology Group studyThe Journal of Pediatrics, 1980
- Histiocytosis X—an analysis of prognostic factorsThe Journal of Pediatrics, 1975
- Histiocytosis X—comparison of three treatment regimensThe Journal of Pediatrics, 1975
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958